What AriBio does

AriBio Co., Ltd. is a clinical-stage biopharmaceutical company founded in 2010 in Seongnam-si, South Korea, developing therapeutics for neurodegenerative and infectious diseases. Its lead asset, AR1001 (mirodenafil), is a once-daily oral second-generation phosphodiesterase-5 (PDE5) inhibitor designed to deliver disease-modifying treatment for early Alzheimer's disease (mild cognitive impairment to mild dementia). The drug exerts polypharmacological effects including neuroprotection, inhibition of tau phosphorylation, suppression of inflammatory responses, and improvement of cerebral blood flow, with demonstrated blood-brain barrier penetration and substantially lower ARIA risk versus approved antibody therapies. AR1001 is currently in the global Phase 3 POLARIS-AD trial, which has completed enrollment of 1,535 patients across approximately 230 clinical centers in 13 countries, supported by IND/CTA approvals from FDA, EMA, MHRA, NMPA, and MFDS. Drug discovery is conducted through the company's proprietary ARIDD™ (AI-powered, Reverse engineered & Integrated Drug Development) platform, which was further integrated with Eli Lilly's Lilly TuneLab AI platform in June 2026.

AriBio operates an asset-light, partnership-driven commercial model. The company retains global development control of AR1001 while licensing regional and global commercialization rights to pharmaceutical partners who fund manufacturing, regulatory, and sales activities in their territories. Current licensees include Fosun Pharma (global — U.S., Europe, Japan, ASEAN, Greater China, with cumulative deal value approaching $4.7 billion), Arcera/Acino (Latin America, Middle East, Southern Africa, Ukraine, Eurasia — $600M deal value), Neuco United (Greater China channel), Samjin Pharmaceutical (South Korea — ~$77M), and RESTARI (polycystic kidney disease and cystic liver diseases — $400M+ potential). Revenue mechanics consist of upfront option fees (e.g., $60M from Fosun in May 2026), milestone payments tied to regulatory and sales achievements, and tiered double-digit royalties on net sales in partner territories.

The company is privately held with no parent entity and 51-100 employees. Co-founders Jai Jun Choung (Chairman and Co-CEO, leading R&D and clinical development) and Soo Hyun Sung (Co-CEO, leading business strategy and fundraising) maintain central leadership. KOSDAQ-listed Solux holds a 15.03% stake following staged investments and is the planned merger counterparty for a KOSDAQ listing transaction targeted for July 10, 2026. Operations are conducted from headquarters in Bundang-gu, Seongnam-si, South Korea and a U.S. office in San Diego, California supporting global clinical development, CMC, and regulatory affairs.

Name

AriBio

Legal name

AriBio Co., Ltd.

Website

http://www.aribio.com/

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

AriBio is a clinical-stage South Korean biopharmaceutical company developing AR1001, an oral PDE5 inhibitor for early Alzheimer's disease currently in global Phase 3 trials. The company licenses commercialization rights to global pharma partners and is pursuing a KOSDAQ listing via merger with Solux.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Neurodegenerative disease therapeutics
• Clinical-stage biopharmaceutical
• Alzheimer's disease treatment
• PDE5 inhibitor drug development
• AI-powered drug discovery

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Global Licensing and Milestone Payments: AriBio generates revenue through upfront option fees, milestone payments upon regulatory achievements (IND approvals, trial completions, regulatory approvals), and tiered double-digit royalties on net sales of licensed products in partner territories. The Fosun Pharma deal includes $60M option fee, $80M upon option exercise, plus milestone payments and royalties.
2. R&D Investment Funding: The company raises investment capital from financial partners (Solux) to fund research and development costs for clinical trials and drug development programs, including Phase 3 trials for AR1001.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

AriBio is a clinical-stage biopharmaceutical company developing AR1001 (mirodenafil), a once-daily oral phosphodiesterase-5 (PDE5) inhibitor with disease-modifying potential for early Alzheimer's disease, currently in a global Phase 3 POLARIS-AD trial. The company also operates the ARIDD AI-powered drug discovery platform, and markets ancillary wellness products (Herzion transcranial vibroacoustic stimulation device, TeloAct hair-loss solution) leveraging its neurodegeneration research.

Product overview

AriBio Co., Ltd. is a clinical-stage biopharmaceutical company developing neurodegenerative disease therapies. The core product is AR1001 (mirodenafil), a best-in-class once-daily oral PDE5 inhibitor in Phase 3 trials for early Alzheimer's disease, being positioned as the first oral disease-modifying treatment for the condition. The company's ARIDD (AI-powered, Reverse engineered & Integrated Drug Development) platform supports its drug discovery pipeline. AriBio has also developed wellness products including Herzion, a transcranial vibroacoustic stimulation device, and TeloAct, a hair-loss solution, leveraging research in neurodegenerative brain disorders. Strategic licensing partnerships have been established with Fosun Pharma (global), Arcera (Latin America, Middle East), Neuco United/Fosun (China), and RESTARI (polycystic kidney disease, cystic liver diseases).

Differentiator

Problem solved

Functional benefit

Products and services

• AR1001 (Mirodenafil) Best-in-class once-daily oral phosphodiesterase-5 (PDE5) inhibitor candidate intended for the treatment of early Alzheimer's disease (mild cognitive impairment to mild dementia). Demonstrates multiple mechanisms including neuroprotection, inhibition of tau phosphorylation, suppression of inflammatory responses, and improvement of cerebral blood flow; favorable safety profile with substantially lower ARIA risk than antibody therapies. Currently in global Phase 3 trial with over 1,500 patients enrolled across 13 countries; commercialized via regional and global licensing partners (Fosun Pharma, Arcera, Neuco United, Samjin Pharmaceutical).
• Herzion Transcranial vibroacoustic stimulation device developed from AriBio's neurodegenerative brain disorder research, marketed as a wellness product.
• TeloAct Hair-loss solution product developed and marketed by AriBio.

Quantifiable outcome

• 69% reduced risk of developing Alzheimer's dementia in sildenafil users (Cleveland Clinic study, Nature Aging)
• +4 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and secondary.

• Eli Lilly (Lilly TuneLab)coreTechnology or Integration · 5 June 2026AriBio joined Lilly TuneLab, an AI-powered drug discovery platform developed by Eli Lilly. The collaboration provides access to AI and machine learning models trained on decades of Eli Lilly research data to support neuroscience drug development. AriBio integrates Lilly TuneLab with its existing ARIDD platform to improve data-driven decision-making and efficiency in developing therapies for neurodegenerative diseases. The company also separately stated it is pursuing a merger with Solux as part of its strategy to expand its biotechnology platform business.
• Fosun PharmacoreGTM or Marketing Partner · 13 May 2026Exclusive global option agreement for AR1001, an oral PDE5 inhibitor for Alzheimer's disease, extending prior regional partnership to worldwide markets (U.S., Europe, Japan). Fosun Pharma pays $60M option fee upfront, with potential additional payments of up to $180M in milestone payments and further sales milestones tied to $2.5B in annual net sales. Total deal value up to $4.7 billion. Fosun handles R&D, manufacturing, regulatory affairs, and commercialization globally. Topline Phase 3 results expected 2026.
• RESTARIcoreStrategic or Co-development Partner · 4 February 2026Exclusive license and commercialization agreement for a small molecule targeting polycystic kidney disease (PKD) and cystic liver diseases (CLD). RESTARI receives exclusive rights outside AriBio's retained territories. Collaboration leverages AriBio's PDE5 inhibitor pre-clinical and clinical development expertise. Transaction includes development, regulatory, and commercial milestone payments plus royalties, with total potential lifetime deal value exceeding $400 million. A letter of intent for co-development of kidney and liver disease therapeutics was signed May 8, 2025.
• Fosun Pharma (ASEAN)coreGTM or Marketing Partner · 7 January 2026Exclusive licensing agreement for AR1001 across 10 ASEAN countries (Singapore, Indonesia, Philippines, Thailand, Vietnam, Cambodia, Laos, Malaysia, Myanmar, Brunei) valued at approximately 630 billion KRW (~$424 million USD). Fosun Pharma handles manufacturing, regulatory licensing, and commercialization in these markets. Cumulative value of global exclusive rights contracts for AR1001 reaches approximately 2.99 trillion KRW.
• Neuco UnitedcoreGTM or Marketing Partner · 28 July 2025Neuco United holds exclusive rights to AR1001 for Greater China (Chinese mainland, Hong Kong SAR, Macau SAR). Arranged licensing agreement with Fosun Pharma for manufacturing and commercialization in Greater China. Neuco United coordinates with AriBio on the ongoing global Phase 3 clinical trial. Three parties to enter technology transfer and supply agreement for commercial readiness in China.
• Arcera (Acino)coreGTM or Marketing Partner · 10 June 2025Exclusive licensing and supply agreements for AR1001 covering Latin America, the Middle East, Southern Africa, Ukraine, and select Eurasian countries. Total deal value estimated at $600 million USD across development, launch, and commercialization period contingent on milestone achievements. Arcera commercializes the product while AriBio manufactures and supplies. Facilitated by KDB Industrial Bank's Global Partnership Support Program.
• Fujirebio DiagnosticscoreTechnology or Integration · 23 April 2025Strategic partnership for biomarker development for Alzheimer's disease and neurodegeneration. AriBio provides plasma and matched CSF samples from the ongoing Phase 3 POLARIS-AD trial. Fujirebio gains access to clinical samples and data, supporting their Lumipulse® platform biomarker development and blood-based diagnostic assays. The partnership fulfilled AriBio's commitment to provide over 1,150 plasma and matched CSF sample sets. Samples continue to be collected for an additional year as part of the extension phase.
• Kentucky Clinical Trial Laboratory (KCTL)secondaryTechnology or Integration · 21 June 2024Strategic collaboration for testing of cerebral spinal fluid (CSF) to aid in Alzheimer's disease diagnosis using the Lumipulse® system. KCTL provides improved access and efficient testing capabilities utilizing both CSF and plasma samples in FDA and EMA approved assays. Supports POLARIS-AD study across North America, EU, UK, and Korea.
• Samjin PharmaceuticalsecondaryGTM or Marketing Partner · 24 March 2024Exclusive marketing rights agreement for AR1001 for Alzheimer's disease in South Korea. Deal valued at 100 billion KRW (~USD 77 million). Samjin Pharmaceutical handles commercialization in the Korean market.
• Fosun Pharma (China)coreGTM or Marketing PartnerOriginal exclusive licensing agreement for AR1001 manufacturing and commercialization in Chinese mainland, Hong Kong, and Macau. Deal executed through Neuco United. Fosun Pharma now expanding to broader ASEAN markets following initial Greater China agreement.
• RESTARI (Co-development)coreStrategic or Co-development PartnerPartnership leveraging AriBio's phosphodiesterase 5 (PDE5) inhibitor technology to co-develop new therapeutics for cystic kidney diseases (including polycystic kidney disease) and chronic liver disease. The collaboration combines drug discovery platforms and expertise from both companies.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AriBio